224 related articles for article (PubMed ID: 28802830)
1. GFAP in early multiple sclerosis: A biomarker for inflammation.
Kassubek R; Gorges M; Schocke M; Hagenston VAM; Huss A; Ludolph AC; Kassubek J; Tumani H
Neurosci Lett; 2017 Sep; 657():166-170. PubMed ID: 28802830
[TBL] [Abstract][Full Text] [Related]
2. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
[TBL] [Abstract][Full Text] [Related]
3. Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis.
Azzolini F; Gilio L; Pavone L; Iezzi E; Dolcetti E; Bruno A; Buttari F; Musella A; Mandolesi G; Guadalupi L; Furlan R; Finardi A; Micillo T; Carbone F; Matarese G; Centonze D; Stampanoni Bassi M
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204724
[No Abstract] [Full Text] [Related]
4. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
[TBL] [Abstract][Full Text] [Related]
5. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
[TBL] [Abstract][Full Text] [Related]
6. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
[TBL] [Abstract][Full Text] [Related]
7. Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
Ahlbrecht J; Martino F; Pul R; Skripuletz T; Sühs KW; Schauerte C; Yildiz Ö; Trebst C; Tasto L; Thum S; Pfanne A; Roesler R; Lauda F; Hecker M; Zettl UK; Tumani H; Thum T; Stangel M
Mult Scler; 2016 Aug; 22(9):1202-14. PubMed ID: 26493127
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
Mult Scler; 2017 Jan; 23(1):62-71. PubMed ID: 27003946
[TBL] [Abstract][Full Text] [Related]
9. Serum GFAP as a biomarker for disease severity in multiple sclerosis.
Abdelhak A; Huss A; Kassubek J; Tumani H; Otto M
Sci Rep; 2018 Oct; 8(1):14798. PubMed ID: 30287870
[TBL] [Abstract][Full Text] [Related]
10. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome.
Sladkova V; Mareš J; Lubenova B; Zapletalova J; Stejskal D; Hlustik P; Kanovsky P
Neurol Res; 2011 May; 33(4):415-20. PubMed ID: 21535941
[TBL] [Abstract][Full Text] [Related]
11. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.
Brettschneider J; Petzold A; Junker A; Tumani H
Mult Scler; 2006 Apr; 12(2):143-8. PubMed ID: 16629417
[TBL] [Abstract][Full Text] [Related]
12. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
de Flon P; Gunnarsson M; Laurell K; Söderström L; Birgander R; Lindqvist T; Krauss W; Dring A; Bergman J; Sundström P; Svenningsson A
Neurology; 2016 Jul; 87(2):141-7. PubMed ID: 27316241
[TBL] [Abstract][Full Text] [Related]
13. Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS.
Novakova L; Singh AK; Axelsson M; Ståhlman M; Adiels M; Malmeström C; Zetterberg H; Borén J; Lycke J; Cardell SL; Blomqvist M
J Neurochem; 2018 Aug; 146(3):322-332. PubMed ID: 29676479
[TBL] [Abstract][Full Text] [Related]
14. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108
[TBL] [Abstract][Full Text] [Related]
15. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
[TBL] [Abstract][Full Text] [Related]
16. A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysis.
Sun M; Liu N; Xie Q; Li X; Sun J; Wang H; Wang M
Mult Scler Relat Disord; 2021 Jun; 51():102870. PubMed ID: 33819724
[TBL] [Abstract][Full Text] [Related]
17. Assessing tissue damage in multiple sclerosis: a biomarker approach.
Burman J; Zetterberg H; Fransson M; Loskog AS; Raininko R; Fagius J
Acta Neurol Scand; 2014 Aug; 130(2):81-9. PubMed ID: 24571714
[TBL] [Abstract][Full Text] [Related]
18. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
[TBL] [Abstract][Full Text] [Related]
19. The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in plasma and CSF.
Ljubisavljevic S; Stojanovic I; Vojinovic S; Stojanov D; Stojanovic S; Cvetkovic T; Savic D; Pavlovic D
Neurochem Int; 2013 Jun; 62(7):988-97. PubMed ID: 23500606
[TBL] [Abstract][Full Text] [Related]
20. The Validation Study of Neurofilament Heavy Chain and 8-hydroxy-2'-deoxyguanosine as Plasma Biomarkers of Clinical/Paraclinical Activity in First and Relapsing-Remitting Demyelination Acute Attacks.
Ljubisavljevic S; Stojanovic I; Basic J; Pavlovic DA
Neurotox Res; 2016 Oct; 30(3):530-8. PubMed ID: 27295058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
